Clinical trial
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac…
NCT00497146 · AbbVie (prior sponsor, Abbott), Industry · Completed
Key facts
| NCT number | NCT00497146 |
|---|---|
| Title | The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 |
| Official title | The PRIMO Study: Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 |
| Acronym | PRIMO |
| Lead sponsor | AbbVie (prior sponsor, Abbott), Industry |
| Collaborators | Massachusetts General Hospital |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Kidney Disease, Left Ventricular Hypertrophy |
| Intervention type | Drug |
| Interventions | paricalcitol, placebo |
| Enrollment | 227 |
| Start date | Feb 1, 2008 |
| Primary completion | Sep 1, 2010 |
| Completion | Mar 1, 2012 |
| First posted | Jul 6, 2007 |
| Last update posted | Mar 12, 2013 |
| Countries | Australia, Czechia, Germany, Italy, Poland, Puerto Rico, Romania, Russia, Spain, Taiwan, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: